Toggle Main Menu Toggle Search

Open Access padlockePrints

Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium

Lookup NU author(s): Professor Ian McKeith, Professor John O'Brien, Emeritus Professor Elaine Perry, Dr Dag Aarsland, Professor David Burn, Professor Raj Kalaria, Dr Elizabeta Mukaetova-Ladinska, Emeritus Professor Robert Perry

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

The dementia with Lewy bodies (DLB) Consortium has revised criteria for the clinical and pathologic diagnosis of DLB incorporating new information about the core clinical features and suggesting improved methods to assess them. REM sleep behavior disorder, severe neuroleptic sensitivity, and reduced striatal dopamine transporter activity on functional neuroimaging are given greater diagnostic weighting as features suggestive of a DLB diagnosis. The 1-year rule distinguishing between DLB and Parkinson disease with dementia may be difficult to apply in clinical settings and in such cases the term most appropriate to each individual patient should be used. Generic terms such as Lewy body (LB) disease are often helpful. The authors propose a new scheme for the pathologic assessment of LBs and Lewy neurites (LN) using alpha-synuclein immunohistochemistry and semiquantitative grading of lesion density, with the pattern of regional involvement being more important than total LB count. The new criteria take into account both Lewy-related and Alzheimer disease (AD)-type pathology to allocate a probability that these are associated with the clinical DLB syndrome. Finally, the authors suggest patient management guidelines including the need for accurate diagnosis, a target symptom approach, and use of appropriate outcome measures. There is limited evidence about specific interventions but available data suggest only a partial response of motor symptoms to levodopa: severe sensitivity to typical and atypical antipsychotics in ∼50%, and improvements in attention, visual hallucinations, and sleep disorders with cholinesterase inhibitors. Copyright © 2005 by AAN Enterprises, Inc.


Publication metadata

Author(s): McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VMY, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M

Publication type: Review

Publication status: Published

Journal: Neurology

Year: 2005

Volume: 65

Issue: 12

Pages: 1863-1872

ISSN (print): 0028-3878

ISSN (electronic): 1526-632X

URL: http://dx.doi.org/10.1212/01.wnl.0000187889.17253.b1

DOI: 10.1212/01.wnl.0000187889.17253.b1

PubMed id: 16237129


Actions

Find at Newcastle University icon    Link to this publication


Share